eMedicine Specialties > Dermatology > Diseases of the Vessels

Varicose Vein Treatment With Endovenous Laser Therapy

Author: Steven E Zimmet, MD, RVT, FACPH, Consulting Staff, Zimmet Vein and Dermatology Clinic; North American Editor, Phlebology: The Journal of Venous Disease; President, American Board of Phlebology
Coauthor(s): Robert Min, MD, Director of Cornell Vascular, Assistant Professor, Department of Radiology, Cornell University Weill Medical College; Craig F Feied, MD, FACEP, FAAEM, FACPh, Professor of Emergency Medicine, Georgetown University School of Medicine; General Manager, Microsoft Enterprise Health Solutions Group
Contributor Information and Disclosures

Updated: Nov 7, 2008

Introduction

Significant advances have occurred in the understanding, diagnosis, and management of venous insufficiency over the last decade or so, mostly owing to the use of duplex ultrasound (DUS) technology. DUS is essential prior to treatment in all patients with CEAP C2 or higher venous disease in order to identify reflux and establish the pattern of disease. (CEAP is a varicosity classification method, in which C is clinical severity, E is etiology, A is anatomy, and P is Pathophysiology.) The Union Internationale de Phlebologie (UIP) has reviewed the objectives and technique of DUS for venous insufficiency.1 An individualized treatment plan is developed based on the history and physical examination, findings of the evaluation, and goals of the patient.

Venous insufficiency from superficial reflux through varicose veins is a serious problem that usually is inexorably progressive if left untreated. Saphenous vein reflux is the underlying primary abnormality in many patients with superficial venous insufficiency.

Stripping of the great saphenous vein (GSV) has been widely agreed upon as essential to minimizing recurrence due to redevelopment of incompetent communication with the saphenofemoral confluence and/or thigh perforator incompetence.

In a traditional surgical approach, ligation and division of the saphenous trunk and all proximal tributaries is followed by stripping or by avulsion phlebectomy. Proximal ligation requires an incision at the groin crease. Stripping of the vein requires additional incisions at the knee or below the knee and is associated with a high prevalence of minor surgical complications. Avulsion phlebectomy requires multiple 2- to 3-mm incisions along the course of the vein and can cause damage to adjacent nerves and lymphatic vessels.

Formerly, stripping of the entire saphenous vein from ankle to groin, along with stab avulsion of varices, had been practiced because it was assumed that reflux extended to the ankle in most patients. However, it was recognized that stripping from the groin to the knee would detach thigh perforators. This fact, along with a high prevalence of saphenous neuralgia associated with groin-to-ankle stripping, explains recommendations for “short” stripping of the GSV from groin to just below the knee that began in the 1980s. One duplex study on more than 500 legs found the most common pattern to be saphenous reflux from the groin to the knee (43.4%), with reflux reaching the ankle in only 1%.2

Endovenous laser ablation (EVLA) is a less invasive alternative to vein stripping. EVLA is routinely performed in an office setting using dilute local anesthesia. EVLA and other minimally invasive techniques, such as radiofrequency ablation and chemical ablation, are increasingly being used instead of surgery to treat incompetent segments of the GSV, small saphenous vein, anterior accessory saphenous vein, and perforators.

Outcomes from EVLA appear to be equal to or better than stripping, with better quality-of-life scores in the postoperative period. EVLA has been shown to correct or significantly improve the hemodynamic abnormality in patients with chronic venous insufficiency (CVI) with superficial venous reflux. Early reports suggest that endovenous ablation techniques, in contrast to surgical stripping, are associated with a low prevalence of neovascularization. See Media Files 1-2 for before-and-after images of EVLA treatment of varicose veins.

The Medscape Dermatologic Surgery Resource Center and Aesthetic Medicine Resource Center may be of interest.

Technology

Endovenous laser ablation (EVLA) works by means of thermal destruction of venous tissues. Laser energy is delivered to the desired incompetent segment inside the vein through a bare laser fiber that has been passed through a sheath to the desired location. A variety of laser wavelengths are in use for this procedure, including 810, 940, 980, 1064 and 1320 nm. When the laser is fired, it deposits thermal energy in the blood and venous tissues, causing irreversible localized venous tissue damage. The laser is most commonly delivered continuously as the laser fiber is gradually withdrawn along the course of the vein until the entire vessel is treated. Although a hole may be created in the vessel wall where the laser beam makes contact with it, permanent ablation of the vein is caused by thermal injury to the entire circumference of the vessel.

Technique

Endovenous laser therapy (EVLT) is of value in the treatment of incompetent truncal varicose veins (eg, GSV, small saphenous vein, accessory saphenous veins). Laser introducer catheters can be passed along small and crooked veins, but they cannot be passed along an extremely tortuous vein with ease.

Ultrasonography is used to confirm and map all areas of reflux and to trace the path of the refluxing great, small, or accessory saphenous trunk from the saphenofemoral/saphenopopliteal junction distally. An appropriate entry point is selected at the distal end of the incompetent segment, at a point that permits cannulation of the vessel with a standard or micropuncture needle introducer. The course of the vein, the junction, and the anticipated entry point are marked on the skin with a surgical marker.

The leg is prepared and draped, and a superficial local anesthetic agent is used to numb the site of cannulation. Ultrasonography is used to guide the needle puncture of the vessel. The Seldinger technique is used to place a guidewire into the vessel, and the guidewire is passed proximally to the saphenofemoral/saphenopopliteal junction. A long introducer sheath (25-70 cm) is passed over the guidewire, which is then removed.

A 400- to 1000-µm sterile, bare-tipped laser fiber is advanced through the sheath until it reaches the proximal end of the sheath. Most laser fibers are marked such that measuring of the fiber is not required. The sheath is then withdrawn over the fiber such that approximately 2-3 cm of bare fiber extends beyond the end of the sheath. With ultrasonographic guidance, the introducer and laser fibers are slightly withdrawn until the laser tip can be clearly observed approximately 2 cm below the junction. At the saphenofemoral junction, the tip should be just below a competent superficial epigastric vein.

Under ultrasonographic guidance, a dilute local anesthetic agent is injected into the tissues surrounding the vein to be treated, within its fascial sheath. An anesthetic is injected along the entire course of the vein from the catheter insertion point to the saphenofemoral junction. In most patients, 150-300 mL of lidocaine 0.1% is sufficient to anesthetize and compress the vessel. Delivering the anesthetic in the correct interfascial location with a volume sufficient to compress the vein and dissect it away from other structures along its entire length is important. Some practitioners prefer a local anesthetic with epinephrine, whereas others prefer not to use epinephrine. The procedure is quick and does not cause early postoperative pain, thus long-acting local anesthetic agents are not needed.

Ultrasonography is used to reconfirm the position of the laser fiber and catheter. Neither the fiber tip nor the laser beam should extend into the femoral vein because injury to the femoral vein may cause deep venous thrombosis (DVT).

When the laser console is switched on, a red aiming beam is visible through the skin. Failure to observe this beam is a reliable indication of malpositioning.

For treatment using intermittent pulsation, the console is generally set to deliver 12-14 J per pulse in 1-second pulses. The laser can be fired manually, but, most often, it is controlled by a foot pedal with automatic pulses at 1-second intervals. The sheath and laser fiber are pulled back approximately 2-3 mm; manual pressure is again applied, and the laser is fired again. This procedure is repeated along the entire length of the vessel to be treated. With pulses delivered once per second at 3-mm intervals, an entire 30-cm greater saphenous vein can be treated in 90 seconds.

For treatment using continuous energy delivery, the energy delivery is similarly set to 12-14 J/s (12-14 W) and the laser fiber is withdrawn at a steady rate of approximately 1 mm/s.

If the vein is small or if the small saphenous vein is being treated, the laser energy may be adjusted to either a lower intensity or a faster pullback.

On rare occasions, the patient experiences momentary pain if the laser is fired in an area with inadequate tumescent anesthesia. Additional delivery of dilute local anesthetic may be indicated.

When the red aiming beam is approximately 2 cm from the entry point, the procedure is complete. The sheath and fiber are withdrawn from the skin, and pressure is applied to the puncture site for a few minutes.

Immediately after the procedure, ultrasonography shows a patent vessel that is in spasm through most or all of its length. Follow-up ultrasonography at 1 week demonstrates nearly 100% early closure of vessels.

Record the watts, laser on-time, total joules delivered, length of the segment treated, and amount and type of local anesthetic used. Calculate the withdrawal rate and joules delivered per centimeter.

Tumescent Anesthesia for EVLA

Endovenous laser ablation (EVLA) should be performed with the patient under local anesthesia using large volumes of a dilute solution of lidocaine and epinephrine (average volume of 150-300 mL of 0.1% lidocaine without or with 1:1,000,000 epinephrine) that is buffered with sodium bicarbonate. This solution should be delivered either manually or with an infusion pump under ultrasonographic guidance so the vein is surrounded with the anesthetic fluid along the entire length of the segment to be treated. See Media File 3. The benefits of tumescent anesthesia for endovenous ablation include the following:

  • Anesthesia
  • Separation of vein to be treated from surrounding structures
  • Thermal sink, which reduces peak temperatures in perivenous tissues
  • Vein compression, which maximizes the effect of treatment on the vein wall

Although the maximum safe dosage of lidocaine using a tumescent technique for venous procedures is not well studied, a dosage of 35 mg/kg is a reasonable estimate. Using these parameters, tumescent anesthesia in the context of liposuction has been shown to be extraordinarily safe. More information is available through Liposuction.com.

EVLA Mechanism of Action

Vein wall injury has been postulated to be mediated both by direct effect and indirectly via laser-induced steam generated by the heating of small amounts of blood within the vein.3 Some authorities have suggested that the choice of wavelength greatly impacts results.4

The main chromophore of 1320-nm lasers, at least initially, is water, while other wavelengths used for endovenous laser ablation (EVLA) primarily target hemoglobin. Obviously, adequately damaging the vein wall with thermal energy is imperative in order to obtain effective ablation. Some heating may occur by direct absorption of photon energy (radiation) by the vein wall, as well as by convection from steam bubbles and conduction from heated blood. However, these later mechanisms are unlikely to account for the majority of the impact on the vein.

The maximum temperature of blood is 100°C. Laser treatment has been found to produce carbonization of the vein wall.5 Carbonization of the laser tip, which occurs at approximately 300°C, is noted following EVLA and seems to occur regardless of the wavelength used. Carbonization of the laser fiber tip creates a point heat source and essentially reduces light penetration into tissue to zero.
 
Mordon et al state "The steam produced by absorption of laser energy by the blood is a tiny fraction of the energy necessary to damage the vein wall and cannot be the primary mechanism of injury to the vein with endovenous laser. The carbonization and tract within the vein walls seen by histology following endovenous laser can only be the result of direct contact between the laser fiber tip and the vein wall."6 Dr Rox Anderson, director of The Wellman Center for Photomedicine at Massachusetts General Hospital, reported that carbon appears to be a secondary but key chromophore that is probably independent of wavelength.7 An ex vivo study on human vein segments supports this concept.8 See Media File 4.

Follow-Up Care

Adequate and proper compression is vitally important after any venous procedure. Compression can reduce the (theoretic) risk of venous thromboembolism, and it is also highly effective in reducing postoperative bruising and tenderness. Note that elastic bandages are not an effective means of compression.

Immediately after the procedure, a class II compression stocking (ie, one with a gradient of 30-40 mm Hg) is applied to the treated leg. Thigh-high– or panty-hose–style stockings are used. The stockings are worn for at least 1 week; they are kept in place continuously for the first 72 hours, but they may be removed for showering thereafter. Bedrest, hot baths, heavy lifting, and long travel are generally forbidden for approximately 1 week, but aerobic activity is encouraged.

Two preliminary reports from 2007  explore the utility of thigh compression after endovenous ablation.9,10 The mean pressure of a class II compression stocking is approximately 15 mm Hg at the thigh level, while short-stretch adhesive bandages achieved a pressure of greater than 40 mm Hg, which is the pressure that has been found to significantly reduce the diameter of the GSV in the thigh.11

The author has measured the mean sub-bandage (pad, short-stretch bandage, 30– to 40–mm Hg stocking) pressure in the mid thigh immediately following EVLA. The mean pressure in active standing position was 55.8 mm Hg (44-68 mm Hg) (Steven E Zimmet, MD, RVT, FACPH, unpublished data, 2008). This is adequate to compress the thigh portion of the GSV and may explain the apparent reduction in pain and bruising that occurs with increased compression.

Lugli and colleagues conducted a prospective randomized study to investigate the effect of an eccentric thigh compression technique on postoperative pain after endovenous laser ablation (EVLA).12 They concluded that eccentric compression significantly reduces postoperative pain. Although the concept of increased thigh compression is antithetical to the idea of graduated compression, it may have clinical utility.

The patient is usually reevaluated between postoperative days 3 and 7, at which time DUS should demonstrate the treated vein to be incompressible and without flow, with no evidence of thrombus in the femoral or popliteal veins.

At 4-6 weeks, an examination should reveal clinical improvement of truncal varices, and an ultrasonographic evaluation should demonstrate a completely closed vessel and no remaining reflux. If any residual open segments or branch veins are noted, sclerotherapy may be performed under ultrasonographic guidance.

Complications

Reports of major complications following endovenous laser ablation (EVLA) are rare. Rates of DVT, pooled from multiple series, are much lower than 1%.13,14,15,16 One group reported a rate of thrombus extension into the femoral vein of 7.7%.17 However, in that study, EVLA, was performed with the patient under general or spinal anesthesia. The fact that patients were not able to ambulate immediately postoperatively may have contributed to the high rate of thrombus extension.

One report described an arteriovenous fistula that developed following EVLA of the short saphenous vein.18 One patient developed septic thrombophlebitis following EVLA combined with open ligation of perforators and stab phlebectomy.19 This resolved with antibiotic treatment and debridement.

Outcomes

Proof-of-concept studies, using vein occlusion/ablation as the main surrogate outcome measure, exist for these techniques. Endovenous laser ablation (EVLA) has a successful initial closure rate of 95-100%. The outcomes appear durable, with a persistent closure rate of 94-97%.13,16,20,21

Significant improvements in physician-measured outcomes such as venous clinical severity scores (VCSS) scores22 and air-plethysmography (APG)23 have been reported following endovenous ablation techniques.

A fundamental advance in medicine is the recognition of the importance of patient-reported measures of quality of life. Several studies have documented significant improvement in quality of life after endovenous treatment, and, comparing endovenous laser with stripping, results generally demonstrate equal or better outcomes with better quality of life in the postoperative period.23,24,25,26,27

Endovenous techniques have largely replaced surgical vein stripping in many countries as the first-line treatment for saphenous incompetence.

Contraindications to EVLA

  • Allergy to local anesthetic
  • Hypercoagulable states
  • Infection of the leg to be treated
  • Lymphedema
  • Nonambulatory patient
  • Peripheral arterial insufficiency
  • Poor general health 
  • Pregnancy
  • Recent or active venous thromboembolism
  • Thrombus or synechiae in the vein to be treated
  • Tortuous GSV, possibly making placement of the laser fiber difficult

Multimedia

Varicose vein before treatment with endovenous la...Media file 1: Varicose vein before treatment with endovenous laser therapy.
Varicose vein before treatment with endovenous la...

Varicose vein before treatment with endovenous laser therapy.

Varicose vein after treatment with endovenous las...Media file 2: Varicose vein after treatment with endovenous laser.
Varicose vein after treatment with endovenous las...

Varicose vein after treatment with endovenous laser.

Transverse ultrasound image of tumescent anesthet...Media file 3: Transverse ultrasound image of tumescent anesthetic fluid surrounding centrally located great saphenous vein and laser fiber/sheath.
Transverse ultrasound image of tumescent anesthet...

Transverse ultrasound image of tumescent anesthetic fluid surrounding centrally located great saphenous vein and laser fiber/sheath.

Carbonization of 600-<font face="symbol">m</font>...Media file 4: Carbonization of 600-m m laser fiber tip secondary to endovenous laser ablation.
Carbonization of 600-<font face="symbol">m</font>...

Carbonization of 600-m m laser fiber tip secondary to endovenous laser ablation.

Keywords

varicose vein treatment, vein treatment, laser vein treatment, endovenous laser ablation, endovenous laser therapy, EVLA, EVLT, saphenous ablation, vein stripping, varicose veins

 
Acknowledgments

The authors and editors of eMedicine gratefully acknowledge the contributions of previous Chief Editor, William D. James, MD, to the development and writing of this article.



More on Varicose Vein Treatment With Endovenous Laser Therapy

References
Further Reading

References

  1. Coleridge-Smith P, Labropoulos N, Partsch H, Myers K, Nicolaides A, Cavezzi A. Duplex ultrasound investigation of the veins in chronic venous disease of the lower limbs--UIP consensus document. Part I. Basic principles. Eur J Vasc Endovasc Surg. Jan 2006;31(1):83-92. [Medline].

  2. Mendoza E. To the topographic anatomy of the vena saphena magna: A duplex sonographische study regarding by surgery relevant aspects. Phlebologie. 2001;30:140-44.

  3. Proebstle TM, Sandhofer M, Kargl A, Gül D, Rother W, Knop J, et al. Thermal damage of the inner vein wall during endovenous laser treatment: key role of energy absorption by intravascular blood. Dermatol Surg. Jul 2002;28(7):596-600. [Medline].

  4. Goldman MP, Mauricio M, Rao J. Intravascular 1320-nm laser closure of the great saphenous vein: a 6- to 12-month follow-up study. Dermatol Surg. Nov 2004;30(11):1380-5. [Medline].

  5. Schmedt CG, Sroka R, Steckmeier S, Meissner OA, Babaryka G, Hunger K, et al. Investigation on radiofrequency and laser (980 nm) effects after endoluminal treatment of saphenous vein insufficiency in an ex-vivo model. Eur J Vasc Endovasc Surg. Sep 2006;32(3):318-25. [Medline].

  6. Mordon SR, Wassmer B, Zemmouri J. Mathematical modeling of endovenous laser treatment (ELT). Accessed July 19, 2006. Biomed Eng Online. Apr 25 2006;5:26. [Medline][Full Text].

  7. Anderson RR. Endovenous Laser: Mechanism of Action. Presented at the Annual Meeting of the American Academy of Dermatology. San Francisco, California, USA: March 3-7, 2006.

  8. Disselhoff BC, Rem AI, Verdaasdonk RM, Kinderen DJ, Moll FL. Endovenous laser ablation: an experimental study on the mechanism of action. Phlebology. 2008;23(2):69-76. [Medline].

  9. Lugli M, Cogo S, Guerzoni S, et al. Effects of eccentric compression after EVLT of great saphenous vein. Presented at the 19th Annual Congress of the American Venous Forum. San Diego, California: February 17, 2007.

  10. Zimmet SE. Endovenous laser ablation. Phlebolymphology. 2007;14:51-8.

  11. Meissner MH, Eklof B, Smith PC, Dalsing MC, DePalma RG, Gloviczki P, et al. Secondary chronic venous disorders. J Vasc Surg. Dec 2007;46 Suppl S:68S-83S. [Medline].

  12. Lugli M, Cogo A, Guerzoni S, Petti A, Maleti O. Effects of eccentric compression by crossed-tape technique after endovenous laser ablation of great saphenous vein: a randomized study. Phlebology. 2009;[in press].

  13. Agus GB, Mancini S, Magi G. The first 1000 cases of Italian Endovenous-laser Working Group (IEWG). Rationale, and long-term outcomes for the 1999-2003 period. Int Angiol. Jun 2006;25(2):209-15. [Medline].

  14. Min RJ, Khilnani NM. Endovenous laser treatment of saphenous vein reflux. Tech Vasc Interv Radiol. Sep 2003;6(3):125-31. [Medline].

  15. Perkowski P, Ravi R, Gowda RC, Olsen D, Ramaiah V, Rodriguez-Lopez JA, et al. Endovenous laser ablation of the saphenous vein for treatment of venous insufficiency and varicose veins: early results from a large single-center experience. J Endovasc Ther. Apr 2004;11(2):132-8. [Medline].

  16. Ravi R, Rodriguez-Lopez JA, Trayler EA, Barrett DA, Ramaiah V, Diethrich EB. Endovenous ablation of incompetent saphenous veins: a large single-center experience. J Endovasc Ther. Apr 2006;13(2):244-8. [Medline].

  17. Mozes G, Kalra M, Carmo M, Swenson L, Gloviczki P. Extension of saphenous thrombus into the femoral vein: a potential complication of new endovenous ablation techniques. J Vasc Surg. Jan 2005;41(1):130-5. [Medline].

  18. Timperman PE. Arteriovenous fistula after endovenous laser treatment of the short saphenous vein. J Vasc Interv Radiol. Jun 2004;15(6):625-7. [Medline].

  19. Dunst KM, Huemer GM, Wayand W, Shamiyeh A. Diffuse phlegmonous phlebitis after endovenous laser treatment of the greater saphenous vein. J Vasc Surg. May 2006;43(5):1056-8. [Medline].

  20. Min RJ, Khilnani N, Zimmet SE. Endovenous laser treatment of saphenous vein reflux: long-term results. J Vasc Interv Radiol. Aug 2003;14(8):991-6. [Medline].

  21. Lu X, Ye K, Li W, Lu M, Huang X, Jiang M. Endovenous ablation with laser for great saphenous vein insufficiency and tributary varices: a retrospective evaluation. J Vasc Surg. Sep 2008;48(3):675-9. [Medline].

  22. Marston WA, Owens LV, Davies S, Mendes RR, Farber MA, Keagy BA. Endovenous saphenous ablation corrects the hemodynamic abnormality in patients with CEAP clinical class 3-6 CVI due to superficial reflux. Vasc Endovascular Surg. Mar-Apr 2006;40(2):125-30. [Medline].

  23. de Medeiros CA, Luccas GC. Comparison of endovenous treatment with an 810 nm laser versus conventional stripping of the great saphenous vein in patients with primary varicose veins. Dermatol Surg. Dec 2005;31(12):1685-94; discussion 1694. [Medline].

  24. Darwood RJ, Theivacumar N, Dellagrammaticas D, Mavor AI, Gough MJ. Randomized clinical trial comparing endovenous laser ablation with surgery for the treatment of primary great saphenous varicose veins. Br J Surg. Mar 2008;95(3):294-301. [Medline].

  25. Mekako AI, Hatfield J, Bryce J, Lee D, McCollum PT, Chetter I. A nonrandomised controlled trial of endovenous laser therapy and surgery in the treatment of varicose veins. Ann Vasc Surg. Jul 2006;20(4):451-7. [Medline].

  26. Rasmussen LH, Bjoern L, Lawaetz M, Blemings A, Lawaetz B, Eklof B. Randomized trial comparing endovenous laser ablation of the great saphenous vein with high ligation and stripping in patients with varicose veins: short-term results. J Vasc Surg. Aug 2007;46(2):308-15. [Medline].

  27. Vuylsteke M, Van den Bussche D, Audenaert EA, Lissens P. Endovenous laser obliteration for the treatment of primary varicose veins. Phlebology. 2006;21(2):80-7.

Further Reading

Bergan JJ ed. The Vein Book. London: Elsevier Science, 2006.
 
Feied CF. Peripheral venous disease. In: Rosen P, Barkin RM, eds. Emergency Medicine: Principles and Practice. 4th ed. St. Louis, Mo: Mosby-Year Book; 1998:chap 107.

Fronek HS, ed. The Fundamentals of Phlebology: Venous Disease for Clinicians, 2nd ed. London: Royal Society of Medicine Press; 2007.
 
Holme JB, Skajaa K, Holme K. Incidence of lesions of the saphenous nerve after partial or complete stripping of the long saphenous vein. Acta Chir Scand. Feb 1990;156(2):145-8.

Kabnick LS. Outcome of different endovenous laser wavelengths for great saphenous vein ablation. J Vasc Surg. 2006 Jan;43(1):88-93.

Mellière D, Almou M, Lellouche D, Becquemin JP, Hoehne M. [Arterial complications following surgery or sclerotherapy of varices]. J Mal Vasc. 1986;11(1):19-22. 
 
Min RJ, Khilnani NM. Endovenous laser treatment of saphenous vein reflux. Tech Vasc Interv Radiol. Sep 2003;6(3):125-31. 
 
Navarro L, Min RJ, Bone C. Endovenous laser: a new minimally invasive method of treatment for varicose veins--preliminary observations using an 810 nm diode laser. Dermatol Surg. Feb 2001;27(2):117-22.

Proebstle TM, Gul D, Kargl A, Knop J. Endovenous laser treatment of the lesser saphenous vein with a 940-nm diode laser: early results. Dermatol Surg. Apr 2003;29(4):357-61.

Staunton MD. Some complications from surgery in varicose veins. Phlebologie. Jan-Mar 1982;35(1):329-35. 
 
Timperman PE. Prospective evaluation of higher energy great saphenous vein endovenous laser treatment. J Vasc Interv Radiol. Jun 2005;16(6):791-4.

Weiss RA, Feied CF, Weiss MA. Vein Diagnosis & Treatment: A Comprehensive Approach. New York, NY: McGraw-Hill; 2001:1-304.

Zimmet SE. Endovenous Ablation. In: Ngyugen T, Alam M, eds. Procedures in Cosmetic Dermatology Series- Leg Veins. London: Elsevier Science, 2006.
 
Zimmet SE. Endovenous laser ablation. Phlebolymphology, 2007;14(2):51-58.

Zimmet SE, Min RJ. Temperature changes in perivenous tissue during endovenous laser treatment in a swine model. J Vasc Interv Radiol. 2003 Jul;14(7):911-5.

Keywords

varicose vein treatment, vein treatment, laser vein treatment, endovenous laser ablation, endovenous laser therapy, EVLA, EVLT, saphenous ablation, vein stripping, varicose veins

Contributor Information and Disclosures

Author

Steven E Zimmet, MD, RVT, FACPH, Consulting Staff, Zimmet Vein and Dermatology Clinic; North American Editor, Phlebology: The Journal of Venous Disease; President, American Board of Phlebology
Steven E Zimmet, MD, RVT, FACPH is a member of the following medical societies: American Academy of Dermatology, American College of Phlebology, American Venous Forum, Australasian College of Phlebology, and Texas Medical Association
Disclosure: Nothing to disclose.

Coauthor(s)

Robert Min, MD, Director of Cornell Vascular, Assistant Professor, Department of Radiology, Cornell University Weill Medical College
Robert Min, MD is a member of the following medical societies: American College of Phlebology, American College of Radiology, American Society for Laser Medicine and Surgery, and Radiological Society of North America
Disclosure: Nothing to disclose.

Craig F Feied, MD, FACEP, FAAEM, FACPh, Professor of Emergency Medicine, Georgetown University School of Medicine; General Manager, Microsoft Enterprise Health Solutions Group
Craig F Feied, MD, FACEP, FAAEM, FACPh is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American College of Phlebology, American College of Physicians, American Medical Association, American Medical Informatics Association, American Venous Forum, Medical Society of the District of Columbia, Society for Academic Emergency Medicine, and Undersea and Hyperbaric Medical Society
Disclosure: Nothing to disclose.

Medical Editor

Smeena Khan, MD, Private Practice, Adult and Pediatric Dermatology Associates
Smeena Khan, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology
Disclosure: Nothing to disclose.

Pharmacy Editor

David F Butler, MD, Professor of Dermatology, Texas A&M University College of Medicine; Chair, Department of Dermatology, Director, Dermatology Residency Training Program, Scott and White Clinic
David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa
Disclosure: 3M Pharmaceutical Grant/research funds Other; Graceway Pharmaceuticals Grant/research funds Other

Managing Editor

Jeffrey J Miller, MD, Associate Professor, Department of Dermatology, Penn State University, Milton S Hershey Medical Center
Disclosure: Nothing to disclose.

CME Editor

Glen H Crawford, MD, Assistant Clinical Professor, Department of Dermatology, University of Pennsylvania School of Medicine; Chief, Division of Dermatology, The Pennsylvania Hospital
Glen H Crawford, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, Phi Beta Kappa, and Society of USAF Flight Surgeons
Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.